Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, and Kelun-Biotech (6990.HK) announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for HBM7575/SKB575, a long-acting bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and an undisclosed target co-developed by the two parties,  for the treatment of asthma. Previously, the first participant has been dosed in a Phase 1 clinical study of HBM7575/SKB575 for the treatment of atopic dermatitis.

"Building on the recent first participant dosing for HBM7575/SKB575 in atopic dermatitis, we are thrilled to see this molecule rapidly advancing into asthma indication." Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, commented. "With two major indications now cleared for clinical development, we look forward to executing our clinical plan and exploring the full potential of this molecule to redefine treatment paradigms for chronic immune-mediated conditions."